Study of a new drug with chemotherapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread or cannot be removed by surgery.
- Your cancer tests positive for a protein called HER2.
- You are generally able to care for yourself (ECOG score 0-1).
- You have not had chemotherapy, targeted therapy, or immunotherapy for this cancer before.
- You agree to use contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.